<DOC>
	<DOCNO>NCT01044771</DOCNO>
	<brief_summary>The study design evaluate proportion patient tenofovir induced proteinuria resolve proteinuria tenofovir contain nucleoside/nucleotide backbone switch raltegravir backbone . Common HIV treatment regimens contain nucleoside/nucleotide combination may long-term side effect include nephrotoxicity . Switching backbone integrase inhibitor base regimen systematically evaluate . Hypothesis : Proteinuria develop treatment tenofovir improve resolve tenofovir switch raltegravir . Switching nuc- spar regimen , contain raltegravir boost protease inhibitor patient without preexist protease inhibitor mutation safe lead virologic failure</brief_summary>
	<brief_title>Pilot Study Raltegravir Switch Resolve Tenofovir Induced Proteinuria</brief_title>
	<detailed_description>As described brief summary , pilot study evaluate improvement proteinuria switch Tenofovir</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Documented HIV infection Ability comply protocol requirement On stable HAART minimum 12 week Evidence TDF induce proteinuria No evidence prior Protease inhibitor failure Treatmentna√Øve integrase inhibitor VL &lt; 200 x 12 week ( minimum 2 viral load measurement ) Active Hepatitis B infection Proteinuria predate tenofovir use PRAMs historic GT PT Life expectancy le 6 month Subjects ongoing AIDS define illness Any condition could compromise safety study subject Grade 3 4 lab abnormality ( excl . grade 3 bilirubin elevation )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>Human immunodeficiency virus</keyword>
	<keyword>tenofovir</keyword>
	<keyword>viread</keyword>
	<keyword>truvada</keyword>
	<keyword>proteinuria</keyword>
</DOC>